Prestige Consumer Healthcare Inc. (NYSE:PBH) Insider William P’pool Sells 8,987 Shares

Prestige Consumer Healthcare Inc. (NYSE:PBH) insider William P’pool sold 8,987 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Prestige Consumer Healthcare Trading Down 0.8 %

Shares of NYSE PBH traded down $0.68 during mid-day trading on Friday, hitting $82.11. The stock had a trading volume of 16,810 shares, compared to its average volume of 249,609. The firm has a market cap of $4.06 billion, a P/E ratio of 20.15, a price-to-earnings-growth ratio of 2.32 and a beta of 0.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The business has a 50 day moving average price of $72.98 and a two-hundred day moving average price of $70.09. Prestige Consumer Healthcare Inc. has a 1 year low of $56.61 and a 1 year high of $83.83.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.07 earnings per share. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in PBH. Paloma Partners Management Co purchased a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter worth about $274,000. Edgestream Partners L.P. bought a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter worth approximately $3,947,000. Martingale Asset Management L P boosted its holdings in Prestige Consumer Healthcare by 0.4% in the third quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock worth $2,666,000 after acquiring an additional 140 shares in the last quarter. Townsquare Capital LLC grew its position in Prestige Consumer Healthcare by 8.8% during the 3rd quarter. Townsquare Capital LLC now owns 77,168 shares of the company’s stock valued at $5,564,000 after purchasing an additional 6,249 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Prestige Consumer Healthcare by 276.2% during the third quarter. BNP Paribas Financial Markets now owns 17,379 shares of the company’s stock valued at $1,253,000 after buying an additional 12,759 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PBH. DA Davidson reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday. Jefferies Financial Group restated a “hold” rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.